Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

659 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Heerspink HJ, Makino H, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Davis JW, Idler K, Kohan DE, Liu M, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D. Heerspink HJ, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2017 Apr;19(4):545-552. doi: 10.1111/dom.12851. Epub 2017 Jan 27. Diabetes Obes Metab. 2017. PMID: 27981738 Clinical Trial.
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH. Palmer AJ, et al. Among authors: de zeeuw d. Diabetes Care. 2004 Aug;27(8):1897-903. doi: 10.2337/diacare.27.8.1897. Diabetes Care. 2004. PMID: 15277414
Renoprotection with and without blood pressure reduction.
Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Laverman GD, et al. Among authors: de zeeuw d. Kidney Int Suppl. 2005 Apr;(94):S54-9. doi: 10.1111/j.1523-1755.2005.09414.x. Kidney Int Suppl. 2005. PMID: 15752241 Free article. Clinical Trial.
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Mix TC, et al. Among authors: de zeeuw d. Am Heart J. 2005 Mar;149(3):408-13. doi: 10.1016/j.ahj.2004.09.047. Am Heart J. 2005. PMID: 15864229
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration.
Dirks JH, de Zeeuw D, Agarwal SK, Atkins RC, Correa-Rotter R, D'Amico G, Bennett PH, El Nahas M, Valdes RH, Kaseje D, Katz IJ, Naicker S, Rodriguez-Iturbe B, Schieppati A, Shaheen F, Sitthi-Amorn C, Solez K, Viberti G, Remuzzi G, Weening JJ; International Society of Nephrology Commission for the Global Advancement of Nephrology Study Group 2004. Dirks JH, et al. Among authors: d amico g, de zeeuw d. Kidney Int Suppl. 2005 Sep;(98):S1-6. doi: 10.1111/j.1523-1755.2005.09800.x. Kidney Int Suppl. 2005. PMID: 16108963 Free article.
Renoprotective effects of renin-angiotensin-system inhibitors.
de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME. de Zeeuw D, et al. Lancet. 2006 Mar 18;367(9514):899-900; author reply 900-2. doi: 10.1016/S0140-6736(06)68374-8. Lancet. 2006. PMID: 16546533 No abstract available.
659 results